Figure 1.
Observations in patients in the highest tertile of aPLA2R1ab levels (150–776 RU/ml). aPLA2R1ab levels decreased to levels <14 RU/ml (the cutoff to define positive and negative) in 23% (three of 13) of patients treated with rituximab, and in 86% (12 of 14) of patients treated with cyclophosphamide. aPLA2R1ab, anti–phospholipase A2 receptor antibody.